From cellular therapy to biologics: non-viral delivery strategies for in vivo CAR-T engineering.
Although CAR-T cell therapy has achieved breakthrough progress in the treatment of hematological malignancies, its current reliance on ex vivo manufacturing presents significant limitations in terms of efficiency, cost, and potential impact on cellular functionality. In vivo CAR-T strategies are increasingly recognized...